Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.85 -0.55 (-1.09%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
36 37 Next >
News headline image
52 Biggest Movers From Yesterday ↗
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
Via Benzinga
News headline image
35 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an... 
Via Benzinga
News headline image
ImmunoGen Shares Rally After Ovarian Cancer Trial Meets Primary Endpoint Goal ↗
ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab... 
Via Benzinga
News headline image
As FINRA's OTC Bulletin Board Closes Down, OTC Markets Group Becomes the Main Gateway Into the Regulated Over-the-Counter Market ↗
Photo by Marga Santoso on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch? ↗
The Swiss pharma needs to get its drug approved first. 
Via The Motley Fool
News headline image
How AI Is Reducing The Costly Toll Of Cancer Drug Development And Disrupting The BioPharma Space ↗
Bio-pharmaceutical investors know full well the drug discovery and development can be a long and uncertain process. Nowhere is that more true than in cancer drugs. This review looks at the history and... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
From Genentech
Via Business Wire
News headline image
Detecting Early Cancer Screening Stocks At An Early Stage Is Critical ↗
If you're going to get cancer, you’re going to want to detect it early. While we’ve come a long way, baby, when it comes to treating terrible maladies like lung... 
Via Benzinga
News headline image
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much ↗
The therapy will likely face stiff competition from more convenient COVID-19 pills. 
Via The Motley Fool
News headline image
Friday Markets Coverage ↗
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
News headline image
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer ↗
The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults... 
Via Benzinga
News headline image
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
News headline image
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes ↗
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4... 
Via Benzinga
News headline image
Why Atea Pharmaceuticals Stock Is Sinking Today ↗
Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy. 
Via The Motley Fool
News headline image
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill ↗
Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
Atea Pharma Stock Collapses As Roche Pulls The Plug On Pfizer-Rivaling Covid Pill ↗
Roche and Atea's partnership will end in February. 
Via Investor's Business Daily
News headline image
Tuesday Market Overview ↗
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
News headline image
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up ↗
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
News headline image
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and... 
Via Benzinga
News headline image
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care ↗
Johnson & Johnson will split its consumer health unit into a publicly traded company. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
News headline image
Veteran's Day ↗
Stock markets took a tumble today across the board, but not as far down as at the opening. 
Via Talk Markets
News headline image
EU Regulator Backs Regeneron-Roche's COVID-19 Drug ↗
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc... 
Via Benzinga
News headline image
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters ↗
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... 
Via Benzinga
News headline image
ALX Oncology Falls After Updated Data For Solid Tumors Candidate ↗
ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/... 
Via Benzinga
News headline image
These OTCQX & OTCQB Securities Had the Most Trading Activity in October ↗
Photo by Burak Kebapci from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
News headline image
The Old Lady Of Threadneedle Street ↗
US markets are up on better jobs growth reported for October today. 
Via Talk Markets
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.